Morepen Laboratories has completed its first commercial dispatch worth ₹50 crore under its ₹825- crore CDMO mandate and expects supplies of around ₹225 crore in Q2 FY2026-27 as it expands manufacturing capacity.
Morepen Laboratories Ltd has commenced commercial execution of its recently announced ₹825 crore Contract Development and Manufacturing Organisation (CDMO) mandate by completing its first commercial dispatch worth approximately ₹50 crore during the first quarter of FY2026-27.
The milestone marks the successful transition of the programme from the validation and qualification phase to full-scale commercial execution.
Commercial supplies gather pace
Following the first shipment, Morepen expects to significantly scale up the programme during the second quarter of FY2026-27.
The company anticipates additional supplies worth around ₹225 crore in Q2FY2026-27, subject to customer schedules as well as regulatory and commercial requirements.
The commencement of commercial supplies strengthens Morepen’s strategy of building long-term global manufacturing partnerships through its expanding CDMO business.
Manufacturing capacity expansion underway
To support larger CDMO opportunities, Morepen is ramping up its manufacturing infrastructure.
The company expects its total reactor capacity to increase to approximately 600 KL by the end of the second quarter, with further expansion planned to 800 KL and eventually 1,000 KL in subsequent phases.
The capacity enhancement is aimed at supporting future customer requirements and scaling up global manufacturing programmes.
Focus on long-term partnerships
Morepen said the start of commercial execution reinforces its strategy of developing a scalable CDMO platform, strengthening customer relationships and participating in long-duration global manufacturing opportunities.
The company is positioning itself to expand its presence in contract manufacturing by leveraging enhanced production capabilities and deeper customer engagement.
Company calls it a key milestone
Morepen Laboratories Ltd Managing Director Sanjay Suri said, “This is an important milestone in Morepen’s transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities.”